Current Illinois CancerCare Clinical Trials

Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using A Circulating Tumor DNA Assay To Detect Minimal Residual Disease (CORRECT-MRD II)

Study Number: NSABP C-14

Study Summary:
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for a minimum of 3 years and up to 5 years for recurrence.

Status: Open

Bloomington, Canton, Galesburg, Ottawa, Pekin, Peoria, Peru, and Washington clinics

Study Coordinator(s)
  • Navigator Carrie, 309-243-3621
  • Beth, 309-243-3617

Study Link

« Search Again